{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.3","upperLimit":"139.7","value":"29.0"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"120.9","value":"41.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"description":"OS was analyzed and listed for the ITT population. Subjects who have not died were censored at the date of last contact which was identified from a visit date, study assessment (physical examination, vital signs, ECOG performance status, electrocardiogram \\[ECG\\], study drug record, radiological evaluation), AE, medication, or disposition information.\n\nOS was calculated using the Kaplan-Meier method. OS at 12 and 24 weeks along with the associated 2-sided 95% CIs were provided. Median OS, first and third quartiles and associated 95% 2-sided CIs were provided.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Subjects with relapsed or refractory malignant mesothelioma regardless of BAP1 status","id":"OG000","title":"Part 1"},{"description":"Subjects with relapsed or refractory BAP1-deficient malignant mesothelioma","id":"OG001","title":"Part 2"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"The patients were assessed for PFS for up to 24 weeks","title":"Part 1 and 2: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Weeks"}